Journal Article (Review Article) DKFZ-2022-02412

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2022
De Gruyter Berlin

Journal of laboratory medicine 46(4), 321 - 330 () [10.1515/labmed-2022-0071]
 GO

This record in other databases:

Please use a persistent id in citations: doi:

Classification:

Note: Mini review / 2567-9430

Contributing Institute(s):
  1. DKTK Koordinierungsstelle München (MU01)
  2. DKTK Koordinierungsstelle Tübingen (TU01)
  3. DKTK Koordinierungsstelle Berlin (BE01)
  4. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)
  5. B063 Krebsgenomforschung (B063)
  6. DKTK HD zentral (HD01)
  7. DKTK Koordinierungsstelle Freiburg (FR01)
  8. DKTK Koordinierungsstelle Frankfurt (FM01)
  9. Personalisierte Medizinische Onkologie (A420)
  10. Verbundinformationssysteme (E260)
  11. DKTK Koordinierungsstelle Dresden (DD01)
Research Program(s):
  1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2022
Database coverage:
Creative Commons Attribution CC BY (No Version) ; DOAJ ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2022-10-17, last modified 2024-09-17



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)